Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Discover Oncology|June 9, 2026
AGPAT family members act as potential predictive biomarkers and therapeutic targets in cervical cancerNannan Gui, Hanyi Pan, Weijuan Lu, et al.Molecular Cancer Therapeutics|October 1, 2025
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-drug Conjugate Demonstrating Superior Anti-Tumor Efficacy and Favorable Safety Profile for Treatment of Solid TumorsYani Peng, Changyong Yang, Liwei Dong, et al.Journal of Inflammation Research|November 26, 2025
Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related DiseasesXiangli Han, Changyong Yang, Zhijun Wang, et al.International Journal of Molecular Sciences|July 27, 2022
Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver DiseaseTieshan Teng, Shuai Qiu, Yiming Zhao, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 25, 2017
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancerXin Li, Changyong Yang, Hong Wan, et al.International Journal of Molecular Sciences|October 27, 2022
Hydrogen Sulfide and Its Donors: Keys to Unlock the Chains of Nonalcoholic Fatty Liver DiseaseXianghui Li, Kaixin Jiang, Yantian Ruan, et al.Frontiers in Surgery|December 1, 2025
Tailored resection of spinal dumbbell schwannomas using transforaminal and modified epidural trans dural sleeve approaches with hemilaminectomyQiaowei Wu, Yihua Rao, Xiaohai Zhang, et al.Molecular Cancer Therapeutics|August 26, 2025
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety ProfileLi-Min Wang, Changyong Yang, Xing Sun, et al.Journal of Cancer Research and Clinical Oncology|December 2, 2019
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trialsJing Luo, Xinchi Dai, Hua Hu, et al.Research and Practice in Thrombosis and Haemostasis|March 20, 2023
BJTJ-1837, a novel FXI activation-blocking antibodyXugang He, Jin Zhang, Yanping Du, et al.Pageof 4